Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia (Q42930614)

11 November 2017

title

Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia (English)

1 reference

11 November 2017

Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia (English)

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

20 June 2024

2

Dolores Di Vizio

1 reference

11 November 2017

Kristine Pelton

1

1 reference

11 November 2017

Luigi Insabato

3

1 reference

11 November 2017

Carl P. Schaffner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20728125

20 June 2024

Michael R. Freeman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20728125

20 June 2024

Keith R. Solomon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20728125

20 June 2024

language of work or name

English

0 references

publication date

21 August 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S0022534710037389?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

https://api.elsevier.com/content/article/PII:S0022534710037389?httpAccept=text/plain

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

http://www.jurology.com/doi/pdf/10.1016/j.juro.2010.05.083

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

20 June 2024

1 reference

11 November 2017

volume

184

1 reference

11 November 2017

issue

4

1 reference

11 November 2017

page(s)

1555-1559

1 reference

Stromal nodules in benign prostatic hyperplasia

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Molecular and cellular pathogenesis of benign prostatic hyperplasia

20 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)

20 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

20 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

20 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

20 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

20 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate

20 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia

20 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate

20 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants

20 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

A signaling network in phenylephrine-induced benign prostatic hyperplasia

20 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Efficacy of candicidin in benign prostatic hypertrophy

20 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Absence of cholesterogenesis regulation in the liver and prostate of the BIO 87.20 hamster

20 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Candicidin: Physiologic effect on prostate

20 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Prostatic cholesterol metabolism: regulation and alteration

20 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Effect of candicidin and colestipol on the testes and prostate glands of BIO 87.20 hamsters

20 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Cystic prostatic hypertrophy in 2 inbred lines of Syrian hamsters.

20 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

20 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Effectiveness of ezetimibe in clinical practice

20 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia

20 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Do statins affect androgen levels in men? Results from the Boston area community health survey

20 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor

20 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

20 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride

20 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.

20 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

The effect of phytosterols on quality of life in the treatment of benign prostatic hyperplasia

20 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.05.083

20 June 2024

Identifiers

1 reference

11 November 2017

1 reference